Why McKesson is not just a low-margin drug wholesaler
McKesson (MCK) is still often described as a pharmaceutical distributor, which is true but incomplete. The company’s latest filings make clear that its model now spans distribution, oncology provider support, prescription-access technology, and a medical-surgical business that is itself headed for separation. That broader setup matters because it changes how investors should think about growth and margins. A pure wholesaler framing understates what McKesson has built around specialty care and healthcare workflow.
The numbers show the scale first. For fiscal 2026, McKesson generated $403.4 billion of revenue, up 12%, and adjusted earnings per diluted share of $39.11, up 18%. Those are not the results of a stagnant low-margin pass-through business. They reflect a portfolio that is adding higher-value services on top of large distribution volumes.
Related Coverage
How oncology and provider solutions are lifting the mix
The clearest evidence is in segment mix. McKesson’s North American Pharmaceutical segment remains the anchor, with fiscal 2026 revenue of $336.7 billion, up 11%, and adjusted segment operating profit of $3.5 billion, up 10%. But the faster-growing part of the story sits next to it. The Oncology & Multispecialty segment produced $48.4 billion of revenue, up 31%, and adjusted segment operating profit of $1.4 billion, up 53%.
That growth is not just acquisition noise. McKesson’s 2026 10-K says the segment includes specialty drug distribution, group purchasing organizations, infusion services, direct-to-patient pharmacy capabilities, cell and gene therapy services, technology solutions, practice consulting, and vaccine distribution. It also supports the U.S. Oncology Network, which the company describes as one of the largest networks of physician-led, community-based oncology practices in the country. In other words, McKesson increasingly sits inside the care workflow, not only inside the product-delivery chain.
That distinction matters because workflow positions are usually stickier than simple product fulfillment. If oncology practices depend on McKesson for distribution, technology, and practice infrastructure at the same time, the relationship is harder to replicate than a standard wholesaling contract.
Why prescription-technology and capital returns deepen the moat
The same logic shows up in Prescription Technology Solutions. In fiscal 2026, that segment generated $5.8 billion of revenue, up 11%, and adjusted segment operating profit of $1.1 billion, up 17%. The 10-K says the business helps solve medication access, affordability, and adherence problems through tools such as electronic prior authorization, price transparency, benefit insight, patient enrollment, dispensing support, and third-party logistics.
This is important because it extends McKesson’s relevance beyond pharmacy shelves. It puts the company into decision points where payers, providers, pharmacies, and biopharma companies all need workflow coordination. That can support better economics than conventional distribution alone.
McKesson also keeps translating that broader mix into cash. The company generated $6.2 billion of cash flow from operations and $5.4 billion of free cash flow in fiscal 2026, then returned $5.1 billion to shareholders, including $4.8 billion in share repurchases and $381 million of dividends. It also entered into a $2.25 billion accelerated share repurchase program and increased repurchase authorization by $5.0 billion in April 2026. That capital-return capacity matters because it shows the portfolio is not only growing, but converting profit into deployable cash.
What investors should watch next: portfolio separation, specialty growth, and execution
The next question is whether McKesson can keep improving its mix while simplifying the portfolio. The Medical-Surgical Solutions segment generated $11.5 billion of fiscal 2026 revenue and $1.0 billion of adjusted segment operating profit, but the company also announced plans to separate that business and struck a deal for Apollo-managed funds to buy a minority interest tied to that strategy. Investors should read that as an attempt to make the remaining company more focused on higher-growth, higher-margin specialty and workflow areas.
Management’s fiscal 2027 adjusted EPS guidance of $43.80 to $44.60, implying 12% to 14% growth, suggests the company believes that mix shift still has room to run. The risk is that specialty growth slows, integration benefits fade, or healthcare reimbursement pressure makes provider solutions less profitable than they look today.
Still, the evergreen thesis is stronger than the old wholesaler label. McKesson remains a huge distributor, but it is increasingly valuable because it also owns oncology infrastructure, access technology, and provider workflow positions that can deepen customer dependence and support better earnings growth.
Key Signals for Investors
Oncology & Multispecialty revenue growth of 31% and adjusted segment operating profit growth of 53% show where McKesson’s mix is becoming more attractive.
Prescription Technology Solutions gives McKesson exposure to medication access and affordability workflows that are less commodity-like than pure drug distribution.
The planned Medical-Surgical separation is worth watching because it could make the remaining company more concentrated in higher-growth specialty and workflow businesses.
Sources
https://www.sec.gov/Archives/edgar/data/927653/000092765326000066/mck_exhibit991x3312026.htm
https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm
.png "Liberty Lifestyle: The Disappearing Art of Hospitality")
